The Competition and Markets Authority (CMA) has decided to close its investigation into the alleged anti-competitive agreements and concerted practices in relation to generic pharmaceutical products.
The watchdog announced its decision is based on administrative priority grounds. The authority further stated that it has not reached a view on whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the parties under investigation.
“This decision does not amount to a statement or finding as to whether the party to the investigation has infringed competition law, nor should any inference be made to that effect,” the authority announced in the closure statement.
The CMA launched the investigation on October 10, 2017, and expanded the scope in July this year, amid the backdrop of rising generics prices that affected community pharmacies hard.
Featured News
Spain’s BBVA Remains Optimistic About Hostile Takeover of Sabadell
Mar 18, 2025 by
CPI
BlackRock, Vanguard and State Street Seek Dismissal of Texas Antitrust Lawsuit
Mar 18, 2025 by
CPI
EU to Boost Metal Sectors with Energy Relief and Safeguards
Mar 18, 2025 by
CPI
Players’ Association Sues Tennis Governing Bodies Over Alleged Antitrust Violations
Mar 18, 2025 by
CPI
Turkey Moves to Curb Big Tech’s Power with New Regulatory Bill
Mar 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li